Paricalcitol in the treatment of secondary hyperparathyroidism

References

• Pitts TO, Piraino BH, Mitro R et al. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J. Clin. Endocrinol. Metab. 67, 876–881 (1988).
   PubMed Web of Science ®Google Scholar
• Reichel H, Deibert B, Schmidt-Gayk H, Ritz E. Calcium metabolism in early chronic renal failure: implications for the pathogenesis of hyperparathyroidism. Nephrol. Dial. Transplant 6, 162–169 (1991).
   PubMed Web of Science ®Google Scholar
• Slatopolsky E, Brown A, Dusso A. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am. J. Kidney Dis. 37, S54–S57 (2001).
   Google Scholar
• Silver J, Kilav R, Naveh-Many T. Mechanisms of secondary hyperparathyroidism. Am. J. Physiol. Renal Physiol. 283, F367–F376 (2002).
   PubMed Web of Science ®Google Scholar
• Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am. J. Kidney Dis. 38, S45–S50 (2001).
   PubMed Web of Science ®Google Scholar
• Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int. 68, 429–436 (2005).
   PubMed Web of Science ®Google Scholar
• Kettler M, Gross M, Ritz E. Calcification and cardiovascular problems in renal failure. Kidney Int. 67(Suppl. 94), S120–S127 (2005).
   Web of Science ®Google Scholar
• Brown AJ, Finch J, Slatopolsky E. Differential effects of 19-nor-1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 on intestinal calcium and phosphorus transport. J. Lab. Clin. Med. 139(5), 279–284 (2002).
   PubMed Web of Science ®Google Scholar
• Holliday LS, Gluck SL, Slatopolsky E, Brown AJ. 1,25-dihydroxy-19-nor-vitamin D(2), a vitamin D analog with reduced bone resorbing activity in vitro. J. Am. Soc. Nephrol. 11, 1857–1864 (2000).
   PubMed Web of Science ®Google Scholar
• Takahashi F, Finch JL, Denda M, Dusso AS, Brown AJ, Slatopolsky E. A new analog of 1,25-(OH)2D3, 19-nor-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am. J. Kidney Dis. 30(1), 105–112 (1997).
   PubMed Web of Science ®Google Scholar
• Finch JL, Brown AJ, Slatopolsky E. Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin-D2 on calcium and phosphorus resorption in bone. J. Am. Soc. Nephrol. 10, 980–985 (1999).
   PubMed Web of Science ®Google Scholar
• Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int. Supp. 56, S14–S19 (1999).
   Web of Science ®Google Scholar
• Hsu CH, Vanholder R, Patel S et al. Subfractions in uremic plasma ultrafiltrate inhibit calcitriol metabolism. Kidney Int. 40, 868–873 (1991).
   PubMed Web of Science ®Google Scholar
• Lu KC, Lin SH, Yu FC et al. Influence of metabolic acidosis on serum 1,25(OH)2D3 levels in chronic renal failure. Miner. Electrolyte Metab. 21, 398–402 (1995).
   PubMedGoogle Scholar
• Sata KA, Gray RW, Lemann J Jr. Urinary excretion of 25-hydroxyvitamin D in health and the nephrotic syndrome. J. Lab. Clin. Med. 99, 325–330 (1982).
   PubMed Web of Science ®Google Scholar
• Jacob AI, Sallman A, Santiz Z et al. Defective photoproduction of cholecalciferol in normal and uremic humans. J. Nutr. 114, 1313–1319 (1984).
   PubMed Web of Science ®Google Scholar
• Slatopolsky E, Finch J, Denda M et al. Phosphorus restriction prevents parathyroid gland growth: high phosphorus directly stimulates PTH secretion in vitro. J. Clin. Invest. 97, 2534–2540 (1996).
   PubMed Web of Science ®Google Scholar
• Almaden Y, Canalejo A, Hernandez A et al. Direct effect of phosphorus on PTH secretion from whole rat parathyroid gland in vitro. J. Bone Miner. Res. 11, 970–976 (1996).
   PubMed Web of Science ®Google Scholar
• Denda M, Finch J, Slatopolsky E. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am. J. Kidney Dis. 28, 596–602 (1996).
   PubMed Web of Science ®Google Scholar
• Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. 31, 607–617 (1998).
   PubMed Web of Science ®Google Scholar
• Ganesh SK, Stack AG, Levin NW et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J. Am. Soc. Nephrol. 12, 2131–2138 (2001).
   PubMed Web of Science ®Google Scholar
• Reslerova M, Moe SM. Vascular calcification in dialysis patients: pathogenesis and consequences. Am. J. Kidney Dis. 42(3 Suppl. 1), S96–S99 (2003).
   PubMed Web of Science ®Google Scholar
• Mee AP, Davenport LK, Hoyland JA, Davies M, Mawer EB. Novel and sensitive detection systems for the vitamin D receptor – in situ reverse transcriptase-polymerase chain reaction and immunogold cytochemistry. J. Mol. Endocrinol. 16, 183–196 (1996).
   PubMed Web of Science ®Google Scholar
• Dusso AS, Brown AJ. Mechanisms of vitamin D action and its regulation. Am. J. Kidney Dis. 32(Suppl.), 13–24 (1998).
   Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism in chronic kidney disease. Am. J. Kidney Dis. 42(Suppl. 3), S1–S201 (2003).
   PubMedGoogle Scholar
• Chapuy MC, Meunier PJ. Vitamin D insufficiency in adults and the elderly. In: Vitamin D. Feldman D, Glorieux FH, Pike JW (Eds). Academic, San Diego, CA, USA, 679–693 (1997).
   Google Scholar
• Goodman WG. Coronary-artery calcifications in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. 342, 1478–1483 (2003).
   Web of Science ®Google Scholar
• Qunibi WY, Nolan CA, Ayus JC. Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon. Kidney Int. Supp. 82, 73–80 (2002).
   Google Scholar
• Mallik NP, Berlyne GM. Arterial calcification after vitamin-D therapy in hyperphosphatemic renal failure. Lancet 2, 1316–1320 (1968).
   PubMed Web of Science ®Google Scholar
• Goldsmith D, Ritz E, Covic A. Vascular calcification: a stiff challenge for the nephrologist; does preventing bone disease cause arterial disease? Kidney Int. 66, 1315–1333 (2004).
   PubMed Web of Science ®Google Scholar
• Sprague SM. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am. J. Kidney Dis. 3(Suppl.), S51–S56 (2001).
   Google Scholar
• Slatopolsky E, Finch J, Ritter C et al. A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am. J. Kidney Dis. 26, 852–860 (1995).
   PubMed Web of Science ®Google Scholar
• Coburn J, Maung H, Elangovan L et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am. J. Kidney Dis. 43(5), 877–890 (2004).
   PubMed Web of Science ®Google Scholar
• Cato A III, Cady WW, Soltanek C, Qasawa B, Chang M, Stoll R. Effect of hemodialysis on the pharmacokinetics of 19-nor-1α25-dihydroxyvitamin D2. Am. J. Kidney Dis. 32, S55–S60 (1998).
   PubMed Web of Science ®Google Scholar
• Brandi L, Egfjord M, Olgaard K. Pharmacokinetics of 1,25 (OH)2D3 and 1(OH)D3 in normal and uraemic men. Nephrol. Dial. Trans. 17, 829–842 (2002).
   Google Scholar
• Staniforth M, Cheng S, Coyne D. Once weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients. Clin. Nephrol. 63(6), 454–460 (2005).
   PubMed Web of Science ®Google Scholar
• Martin KJ, Gonzalez E, Lindberg JS et al. Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study. Am. J. Kidney Dis. 38(5 Suppl. 5), S57–S63 (2001).
   PubMed Web of Science ®Google Scholar
• Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 63, 1483–1490 (2003).
   PubMed Web of Science ®Google Scholar
• Llach F, Keshav G, Glodblat MV et al. Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2. Am. J. Kidney Dis. 32, S48–S54 (1998).
   PubMed Web of Science ®Google Scholar
• Lindberg J. A long term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin. Nephrol. 56, 315–323 (2001).
   PubMed Web of Science ®Google Scholar
• Coyne DW, Grieff M, Ahya SN, Giles K, Norwood K, Slatapolsky E. Differential effects of acute administration of 19-nor-1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am. J. Kidney Dis. 40, 1283–1288 (2002).
   PubMed Web of Science ®Google Scholar
• Marin KJ, Gonzalez EA, Gellens M et al. 19-Nor-1-α-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J. Am. Soc. Nephrol. 9, 1427–1432 (1998).
   PubMed Web of Science ®Google Scholar
• Slatopolsky E, Cozzolino M, Lu Y. Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparthyroid bone disease in experimental uremia. Kidney Int. 63, 2020–2027 (2003).
   PubMed Web of Science ®Google Scholar
• Martin KJ, Gonzalez EA, Gellens ME, Hamm LL, Abboud H, Lindberg J. Therapy of secondary hyperparathyroidism with 19-nor-1α, 25-dihydroxyvitamin D2. Am. J. Kidney Dis. 32(2 Suppl. 2), S61–S66 (1998).
   PubMed Web of Science ®Google Scholar
• Martin KJ, Gonzalez EA. Vitamin D analogs for the management of secondary hyperparathyroidism. Rev. Port. Nefrol. Hipert. 19(Suppl. 1), 81–86 (2005).
   Google Scholar
• Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus M, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N. Eng. J. Med. 349, 446–456 (2003).
   PubMed Web of Science ®Google Scholar
• Dobrez DG, Mathes A, Amdahl M et al. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol. Dial. Transplant 19, 1174–1181 (2004).
   PubMed Web of Science ®Google Scholar
• Coyne D, Acharya M, Qiu P et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Am. J. Kidney Dis. 47, 263–276 (2005).
   Google Scholar
• Agarwal R, Acharya M, Tian J et al. Antiproteinuric effects of oral paricalcitol in chronic kidney disease. Kidney Int. 68, 2823–2828 (2005).
   PubMed Web of Science ®Google Scholar
• Baker LR, Abrams L, Roe CJ et al. 1,25(OH)2D3 administration in moderate renal failure: a prospective double blind trial. Kidney Int. 35, 661–669 (1989).
   PubMed Web of Science ®Google Scholar
• Nordal KP, Dahl E. Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J. Clin. Endocrinol. Metab. 67, 929–936 (1988).
   PubMed Web of Science ®Google Scholar
• Coburn J, Maung H, Elangovan L et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am. J. Kidney Dis. 43(5), 877–890 (2004).
   PubMed Web of Science ®Google Scholar
• Hamdy NA et al. Effect of alfacalcidol on natural course of renal bone disease in mild and moderate renal failure. BMJ 310(6976), 358–363 (1995).
   PubMed Web of Science ®Google Scholar
• Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet 351, 805–806 (1998).
   PubMed Web of Science ®Google Scholar
• Couttenye MM, D’Haese P, Verschoren WJ et al. Low bone turnover in patients with renal failure. Kidney Int. 56(Suppl. 73), S70–S76 (1999).
   Google Scholar
• Coen G, Ballanti P, Bonucci E et al. Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron 91, 103–111 (2002).
   PubMed Web of Science ®Google Scholar
• Nemeth EF, Heaton WH, Miller M et al. Pharmacodynamics of the type II calcimimetics compound cinacalcet HCl. J. Pharmacol. Exp. Ther. 308, 627–635 (2004).
   PubMed Web of Science ®Google Scholar
• Cardus A, Gallego C, Muray S et al. Differential effect of vitamin D analogues on the proliferation of vascular smooth muscle cells. Nefrologia 23(Suppl. 2), 117–121 (2003).
   PubMed Web of Science ®Google Scholar